Jubilant Pharmova’s wholly owned subsidiary -- Jubilant Biosys’ (JBL) subsidiary -- Jubilant Biosys Innovative Research Services Pte, Singapore has signed and issued a ‘put option offer’ to Pierre Fabre Laboratories, which sets forth an offer to acquire 80% equity capital (around Euro 4.4 million over a period of 2 years) in a new company to be incorporated in France, which new company shall acquire Pierre Fabre’s R&D Centre (Including R&D Site and R&D activities) at Saint Julien, France.
The R&D centre has a capability of conducting discovery and preclinical development activities in immune-oncology. The facilities include research labs & office space including parking area surrounded by green field.
Pierre Fabre Laboratories may invest 20% equity capital (around Euro 1.1 million over a period of 2 years) in a new company for a maximum period of 5 years, during which time they may continue to provide support to the new company. In addition to that, Pierre Fabre Laboratories may also hire services from Jubilant Biosys aggregating to Euro 7 million for first 4 years post-closing date.
Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.
